Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a Two-Drug punch revive immunotherapy for tough bladder cancers?

NCT ID NCT06439836

Recruiting now Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 07, 2026 · Updated 5 times

Summary

This early-phase trial is testing whether adding an experimental drug called emavusertib (CA-4948) to the immunotherapy pembrolizumab can help patients with advanced urothelial cancer whose tumors have become resistant to PD-1/PD-L1 blockers. The study will enroll 27 adults and focus on finding the safest dose and checking for side effects, while also watching for any signs that the combination might shrink tumors. It is currently recruiting participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
emavusertib (CA-4948) combined with pembrolizumab
What this could lead to
If successful, this could point toward a new treatment option for patients whose urothelial cancer has stopped responding to standard immunotherapy.
What could go wrong
This is a very early Phase 1 trial with only 27 people, so safety and the right dose are the main goals—not yet proof of effectiveness. The combination may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC UROTHELIAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bladder transitional cell carcinoma transitional cell carcinoma urinary bladder carcinoma urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC UROTHELIAL CARCINOMA UNRESECTABLE UROTHELIAL CARCINOMA

Contacts and locations

Locations

  • City of Hope Comprehensive Cancer Center

    RECRUITING

    Duarte, California, 91010, United States

    Contact Email: •••••@•••••

  • Emory Saint Joseph's Hospital

    RECRUITING

    Atlanta, Georgia, 30342, United States

  • Emory University Hospital Midtown

    RECRUITING

    Atlanta, Georgia, 30308, United States

  • Emory University Hospital/Winship Cancer Institute

    RECRUITING

    Atlanta, Georgia, 30322, United States

  • Mount Sinai Hospital

    RECRUITING

    New York, New York, 10029, United States

  • NYP/Weill Cornell Medical Center

    RECRUITING

    New York, New York, 10065, United States

  • UC Irvine Health/Chao Family Comprehensive Cancer Center

    RECRUITING

    Orange, California, 92868, United States

    Contact Email: •••••@•••••

  • UC San Diego Moores Cancer Center

    RECRUITING

    La Jolla, California, 92093, United States

    Contact Email: •••••@•••••

  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

    RECRUITING

    Irvine, California, 92612, United States

    Contact Email: •••••@•••••

  • UT Southwestern/Simmons Cancer Center-Dallas

    RECRUITING

    Dallas, Texas, 75390, United States

    Contact Email: •••••@•••••

  • University of Miami Miller School of Medicine-Sylvester Cancer Center

    RECRUITING

    Miami, Florida, 33136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.